Publications by authors named "Dennis Ruff"

Claim this Profile
A
A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang

Clin Transl Sci· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults.
Kimberly A Ramos, Ian E James, Franck Skobieranda, David G Soergel, Dennis Ruff

Clin Pharmacol Drug Dev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor.
Ian E James, Franck Skobieranda, David G Soergel, Kimberly A Ramos, Dennis Ruff

Clin Pharmacol Drug Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
John P Hanrahan, James D Wakefield, Phebe J Wilson, Marina Mihova, Jennifer G Chickering, Dennis Ruff

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does GLP-1 suppress its own basal secretion?
Dariush Elahi, Dennis A Ruff, Olga D Carlson, Graydon S Meneilly, Joel F Habener

Endocr Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of an effect of T89 on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Ping Wang, He Sun, Liu Yang, Ling-Yan Li, Jing Hao, Dennis Ruff

J Clin Pharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Dennis Ruff

Clin Ther· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Dennis Ruff

Clin Ther· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Dennis Ruff, David Crockford, Gino Girardi, Yuxin Zhang

Ann N Y Acad Sci· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Graham Scott, Christiane Rordorf, Christine Reynolds, Jyoti Kalbag, Michael Looby, Dennis A Ruff

Clin Pharmacokinet· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis